TY - JOUR
T1 - Acromegaly and the risk of cancer
T2 - a nationwide population-based cohort study in Korea
AU - Kim, Yeo Song
AU - Yun, Jae Seung
AU - Kim, Hyunho
AU - Jeun, Sin Soo
AU - Kim, Bongseong
AU - Lee, Sea Won
AU - Lee, Jung Eun
AU - Kim, Kyuho
AU - Ko, Seung Hyun
AU - Ahn, Yu Bae
AU - Han, Kyungdo
AU - Yang, Seung Ho
N1 - Publisher Copyright:
© The Author(s) 2025. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved.
PY - 2025/3/1
Y1 - 2025/3/1
N2 - Introduction: Using a nationwide population-based cohort, we primarily investigated whether overall and site-specific cancer risks are increased in patients with acromegaly. Patients and methods: The study included 2382 patients with acromegaly and 11 910 controls aged above 20, from 2006 to 2016. Cox hazards regression analysis was used, adjusting for baseline covariates. To investigate the association between acromegaly and cancer risk, we conducted Cox proportional hazards regression analysis with adjustments for age, sex, hypertension, diabetes, and dyslipidemia, and stratified the analysis by age (<50, 50-64, and ≥65 years), sex, and follow-up duration (<1, 1-4, and ≥5 years). Results: Among the 2382 patients with acromegaly, overall cancer occurred in 244 (10.2%), while the 11 910 controls had 707 (5.9%) occurrences (HR: 1.90 (95% confidence interval (CI): 1.63-2.22). Patients with acromegaly had the highest relative risk for brain cancers with an HR of 6.80 (95% CI: 2.83-16.38) and significantly higher risk of lymphoma, thyroid cancer, multiple myeloma, pancreatic cancer, and colorectal cancer. Even 5 years after the diagnosis of acromegaly, patients continued to show a significantly higher incidence of cancer. The overall cancer risk, particularly for stomach cancer, was significantly higher in patients under the age of 50 compared to older patients. No significant difference was observed between sexes. Conclusions: This nationwide longitudinal cohort study shows an increased risk of cancer in patients with acromegaly Active and long-term cancer screening is necessary in patients with acromegaly.
AB - Introduction: Using a nationwide population-based cohort, we primarily investigated whether overall and site-specific cancer risks are increased in patients with acromegaly. Patients and methods: The study included 2382 patients with acromegaly and 11 910 controls aged above 20, from 2006 to 2016. Cox hazards regression analysis was used, adjusting for baseline covariates. To investigate the association between acromegaly and cancer risk, we conducted Cox proportional hazards regression analysis with adjustments for age, sex, hypertension, diabetes, and dyslipidemia, and stratified the analysis by age (<50, 50-64, and ≥65 years), sex, and follow-up duration (<1, 1-4, and ≥5 years). Results: Among the 2382 patients with acromegaly, overall cancer occurred in 244 (10.2%), while the 11 910 controls had 707 (5.9%) occurrences (HR: 1.90 (95% confidence interval (CI): 1.63-2.22). Patients with acromegaly had the highest relative risk for brain cancers with an HR of 6.80 (95% CI: 2.83-16.38) and significantly higher risk of lymphoma, thyroid cancer, multiple myeloma, pancreatic cancer, and colorectal cancer. Even 5 years after the diagnosis of acromegaly, patients continued to show a significantly higher incidence of cancer. The overall cancer risk, particularly for stomach cancer, was significantly higher in patients under the age of 50 compared to older patients. No significant difference was observed between sexes. Conclusions: This nationwide longitudinal cohort study shows an increased risk of cancer in patients with acromegaly Active and long-term cancer screening is necessary in patients with acromegaly.
KW - acromegaly
KW - cancer
KW - epidemiology
KW - screening
UR - https://www.scopus.com/pages/publications/105001042063
U2 - 10.1093/ejendo/lvaf029
DO - 10.1093/ejendo/lvaf029
M3 - Article
C2 - 40037898
AN - SCOPUS:105001042063
SN - 0804-4643
VL - 192
SP - 220
EP - 227
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 3
ER -